Wild-type and modified gp100 peptide-pulsed dendritic cell vaccination of advanced melanoma patients can lead to long-term clinical responses independent of the peptide used. Nov 2010 - Cancer Immunol. Immunother.:1432-0851 [PMID:21069321] [Lesterhuis WJ] [Schreibelt G] [Scharenborg NM] [Brouwer HM] [Gerritsen MJ] [Croockewit S] [Coulie PG] [Torensma R] [Adema GJ] [Figdor CG] [de Vries IJ] [Punt CJ]
Dendritic cell vaccination in combination with anti-CD25 monoclonal antibody treatment, a phase I/II study in metastatic melanoma patients. Aug 2010 - :1078-0432 [PMID:20736326] [Jacobs JF] [Punt CJ] [Lesterhuis WJ] [Sutmuller RP] [Brouwer HM] [Scharenborg NM] [Klasen IS] [Hilbrands LB] [Figdor CG] [de Vries IJ] [Adema GJ]
Vaccination of colorectal cancer patients with CEA-loaded dendritic cells: antigen-specific T cell responses in DTH skin tests. May 2006 - Ann. Oncol.; 17(6):0923-7534 [PMID:16600979] [Lesterhuis WJ] [de Vries IJ] [Schuurhuis DH] [Boullart AC] [Jacobs JF] [de Boer AJ] [Scharenborg NM] [Brouwer HM] [van de Rakt MW] [Figdor CG] [Ruers TJ] [Adema GJ] [Punt CJ]
